Regeneus Ltd. (AU:CMB) has released an update.
Cambium Bio Limited has released its annual financial results for the year ended June 30, 2024, reporting a staggering 100% increase in revenue from ordinary activities but also a significant 34% decrease in net profit attributable to members. No dividends were paid or proposed this year, and the company’s basic and diluted earnings per share dropped to negative 0.19 cents. The full details of the financial performance, audited by Stantons International Audit and Consulting Pty Ltd, are included in the annual report and the preliminary final report.
For further insights into AU:CMB stock, check out TipRanks’ Stock Analysis page.
